Additionally, research data have indicated that voxtalisib-targeted inhibition of PI3K/mTOR is a promising treatment strategy to reduce the tumour burden of patients with glioblastoma (GBM) (Zhao et al., 2019). Here, PIK3CA is linked to glioblastoma.